Regeneron Pharmaceuticals announced its financial results for the second quarter of 2025, reporting revenues of $3.68 billion, a 4% increase compared to the same period in 2024. Key highlights include a 22% rise in global net sales of Dupixent to $4.34 billion and a 29% increase in U.S. net sales of EYLEA HD to $393 million. The company achieved GAAP earnings per share of $12.81, a 3% increase, while non-GAAP earnings per share rose 12% to $12.89. The FDA granted approval for Lynozyfic for multiple myeloma and additional indications for Dupixent, further enhancing the company's product portfolio.
In addition to its financial performance, Regeneron has made significant investments in manufacturing and returned over $2.3 billion to shareholders through share repurchases and dividends. The company has approximately 45 product candidates in clinical development, including advancements in its oncology portfolio and new indications for existing products. The anticipated regulatory approvals for EYLEA HD are expected to be delayed due to a recent FDA inspection. Regeneron continues to focus on expanding its pipeline and addressing various serious diseases through innovative therapies.
linkAug 01, 2025 06:49:57
Regeneron Pharmaceuticals reported first quarter 2025 revenues of $3.0 billion, with a GAAP diluted earnings per share (EPS) of $7.27 and a non-GAAP diluted EPS of $8.22. The company's Dupixent® global net sales rose 19% to $3.67 billion, while EYLEA HD® U.S. net sales increased 54% to $307 million. However, total EYLEA HD and EYLEA U.S. net sales decreased 26% to $1.04 billion. The company received regulatory approvals for Dupixent in chronic spontaneous urticaria in the U.S. and chronic obstructive pulmonary disease in Japan, and the FDA accepted priority review for EYLEA HD's supplemental Biologics License Application for retinal vein occlusion and monthly dosing in approved indications. Additionally, Lynozyfic™ was approved in the EU for multiple myeloma, and regulatory applications for Libtayo® in adjuvant cutaneous squamous cell carcinoma were submitted in the U.S. and EU.
In terms of financial performance, Regeneron's GAAP net income for the first quarter was $809 million, a 12% increase from the prior year, while non-GAAP net income decreased by 17% to $928 million. The company announced ongoing investments in infrastructure and manufacturing in New York and North Carolina, expected to exceed $7 billion. Regeneron also initiated a new share repurchase program, authorizing up to $3 billion, and declared a cash dividend of $0.88 per share, payable in June 2025. The company continues to focus on advancing its clinical pipeline, with 45 product candidates currently in development.
linkApr 29, 2025 06:37:44
Regeneron Pharmaceuticals announced a revenue increase of 10% in the fourth quarter of 2024, reaching $3.79 billion, and an 8% rise for the full year, totaling $14.20 billion. Notable highlights include a 15% increase in global net sales of Dupixent to $3.70 billion in the fourth quarter, and a 50% increase in global net sales of Libtayo to $367 million. The company also initiated a quarterly cash dividend program and expanded its share repurchase capacity to approximately $4.5 billion.
On the downside, Regeneron reported a 21% decrease in GAAP net income for the fourth quarter, dropping to $918 million, and a 21% decline in GAAP diluted earnings per share to $8.06. Additionally, the company faced challenges with EYLEA sales, which saw an 11% decrease in U.S. net sales compared to the previous year. The overall operating expenses also rose, particularly in research and development, which increased by 20% in the fourth quarter, indicating higher costs associated with advancing their clinical pipeline.
linkFeb 04, 2025 07:11:05
Regeneron Pharmaceuticals presented updates on its clinical pipeline at the J.P. Morgan Healthcare Conference, highlighting significant achievements such as Dupixent® now treating over a million patients globally and the recent approval for chronic obstructive pulmonary disease (COPD) with strong payer coverage. The company reported combined U.S. net product sales of $6 billion for EYLEA products in 2024, indicating a 1% year-over-year growth. Additionally, Libtayo® surpassed $1 billion in sales, supported by a successful Phase 3 study in high-risk cutaneous squamous cell carcinoma, demonstrating a significant reduction in disease recurrence risk compared to placebo.
However, the company faces challenges, including increasing competition in the anti-VEGF category, which could impact future sales. The report noted that EYLEA's net product sales were positively influenced by higher wholesaler inventory levels, which may not be sustainable. Furthermore, the presence of adverse events associated with Libtayo, including a higher incidence of grade ≥3 adverse events compared to placebo, raises concerns about treatment safety. These factors could affect Regeneron's market position and future growth potential.
linkJan 13, 2025 06:37:41
Regeneron Pharmaceuticals reported a revenue increase of 11% in the third quarter of 2024, reaching $3.72 billion compared to $3.36 billion in the same period last year. Notable growth was seen in global net sales of Dupixent, which rose by 23% to $3.82 billion, and Libtayo's global sales increased by 24% to $289 million. The company's GAAP diluted earnings per share also rose significantly, increasing by 30% to $11.54. Additionally, the FDA approved Dupixent as the first biologic therapy for chronic obstructive pulmonary disease (COPD), marking a significant milestone for the company.
On the downside, Regeneron faced challenges with EYLEA sales, which saw a decrease in net sales of 21% compared to the previous year. The company reported increased operating expenses, particularly in research and development, which rose by 18% to $1.27 billion, reflecting the advancement of its clinical pipeline. Furthermore, the company experienced an unfavorable $0.43 impact from an acquired in-process research and development charge, which affected its earnings. Despite these challenges, Regeneron continues to invest in its diverse clinical portfolio and aims to maximize shareholder returns.
linkOct 31, 2024 07:10:23
Regeneron Pharmaceuticals reported a robust second quarter in 2024, with revenues up 12% to $3.55 billion, driven by significant sales growth of Dupixent and Libtayo. GAAP earnings per share rose 46% to $12.41. The European Commission approved Dupixent for COPD, marking a key milestone. However, an unfavorable charge impacted earnings slightly. Overall, the company is optimistic about its clinical pipeline and future growth.
linkAug 01, 2024 07:06:07
Regeneron's Q1 revenues slightly dropped, but excluding one product, they increased. Dupixent and EYLEA HD sales surged. GAAP diluted EPS was $6.27. A new $3.0 billion share repurchase program was authorized. The company highlighted progress in its pipeline, including approvals for EYLEA HD and Dupixent in new indications. Positive data was shared for oncology programs, though some FDA Complete Response Letters were received. Corporate updates included acquiring 2seventy bio's pipeline and collaborating with Mammoth Biosciences for research.
linkMay 02, 2024 07:06:29
Regeneron reported a 1% increase in Q4 2023 revenues, 8% increase in full year 2023 revenues, and positive sales growth for key products like Dupixent and EYLEA HD. The company also achieved progress in its R&D pipeline with multiple regulatory submissions and approvals. However, there was a 3% decrease in GAAP net income and a 6% decrease in non-GAAP net income for the fourth quarter of 2023.
linkFeb 02, 2024 07:16:11
Regeneron Pharmaceuticals presented achievements and pipeline progress at the J.P.Morgan Healthcare Conference. Key highlights include FDA approval and successful launch of Eylea HD, exceptional Dupixent performance, and significant progress in immuno-oncology pipeline. The company emphasized potential opportunities in hematology, genetic medicine, and obesity pipelines. However, the presentation also included a disclaimer about forward-looking statements and associated risks.
linkJan 08, 2024 06:30:44
Regeneron Pharmaceuticals reported a 15% increase in revenues for the third quarter of 2023, driven by strong performance of Dupixent and Libtayo. The company also achieved significant pipeline progress, including FDA approvals for EYLEA HD and Veopoz, and FDA priority review designations for odronextamab and Dupixent in pediatric eosinophilic esophagitis. Additionally, Regeneron completed the acquisition of Decibel Therapeutics, strengthening its genetic medicines portfolio.
linkNov 02, 2023 07:10:07